§
Luxuse
Patent Intelligence
Sign In
Patent US6491938B2 successfully refreshed from Google Patents.
← Back to Patent Explorer
US6491938B2 Expired / Lapsed US ⏱️ 0.0 years remaining

Therapeutic inhibitor of vascular smooth muscle cells

Assignee: UAB Research Foundation
•
Filing: 2001-06-29
•
Granted: 2002-12-10
•
Expires: 2021-06-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.

Inventors

  • 👤 Lawrence L. Kunz
  • 👤 John M. Reno

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 12:54
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K31/00; A61K31/04; A61K31/13; A61K31/131; A61K31/135; A61K31/138; A61K31/16; A61K31/165; A61K31/17; A61K31/33; A61K31/335; A61K31/337; A61K31/365; A61K31/395; A61K31/40; A61K31/4025; A61K31/403; A61K31/4035; A61K31/407; A61K31/495; A61K31/505; A61K31/519; A61K31/55; A61K31/551; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6807; A61K47/6809; A61K47/6811; A61K47/6817; A61K47/6831; A61K47/6835; A61K47/6843; A61K47/69; A61K47/6921; A61K47/6927; A61L; A61L31/00; A61L31/14; A61L31/148; A61L31/16; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/602; A61L2300/606; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/323; Y; Y10; Y10S; Y10S435/00; Y10S435/975

Claims Analysis

Total Claims: 19
Claim 1
Independent Claim 65 words
A kit comprising an implantable device adapted for the delivery of at least one therapeutic agent to a site in the lumen of a traumatized mammalian vessel and a unit dosage form comprising at least one cytoskeletal inhibitor in a liquid vehicle, wherein the administration of at least a portion of the unit dosage form to the vessel is effective to biologically stent the vessel.
Claim 2
Dependent Claim 65 words
A kit comprising an implantable device adapted for the delivery of at least one therapeutic agent to a site in the lumen of a traumatized mammalian vessel and a unit dosage form comprising at least one cytoskeletal inhibitor in a liquid vehicle, wherein the administration of at least a portion of the unit dosage form to the vessel is effective to biologically stent the vessel.
Claim 3
Dependent Claim 41 words
The kit of claim 1 wherein the administration is sufficient for at least a portion of the unit dosage form to penetrate to at least about the inner 6 to 9 cell layers of the inner tunica media of the vessel.
Claim 4
Dependent Claim 17 words
The kit of claim 1 wherein the cytoskeletal inhibitor comprises taxol, a cytochalasin, or an analog thereof.
Claim 5
Dependent Claim 11 words
The kit of claim 3 wherein the cytoskeletal inhibitor comprises taxol.
Claim 6
Dependent Claim 14 words
The kit of claim 3 wherein the cytoskeletal inhibitor comprises an analog of taxol.
Claim 7
Dependent Claim 14 words
The kit of claim 3 wherein the cytochalasin comprises an analog of cytochalasin B.
Claim 8
Dependent Claim 11 words
The kit of claim 3 wherein the cytochalasin comprises cytochalasin A.
Claim 9
Dependent Claim 11 words
The kit of claim 3 wherein the cytochalasin comprises cytochalasin D.
Claim 10
Dependent Claim 11 words
The kit of claim 3 wherein the cytochalasin comprises cytochalasin B.
Claim 11
Dependent Claim 21 words
The kit of claim 9 wherein cytochalasin B is at about 0.01 to about 10 μg per ml of liquid vehicle.
Claim 12
Dependent Claim 21 words
The kit of claim 9 wherein cytochalasin B is at about 1.0 to about 10 μg per ml of liquid vehicle.
Claim 13
Dependent Claim 10 words
The kit of claim 1 wherein the vehicle is aqueous.
Claim 14
Dependent Claim 12 words
The kit of claim 1 wherein the implantable device is a catheter.
Claim 15
Dependent Claim 25 words
The kit of claim 13 wherein the implantable device is a catheter which delivers about 4 to about 25 ml of the unit dosage form.
Claim 16
Dependent Claim 27 words
The kit of claim 14 wherein the unit dosage form is administered for about 1 to about 5 minutes at about 0.3 atm to about 8 atm.
Claim 17
Dependent Claim 20 words
The kit of claim 13 wherein the catheter pore size is about 0.1 microns to about 8 microns in diameter.
Claim 18
Dependent Claim 36 words
The kit of claim 9 wherein the unit dosage form comprises a vial comprising about 10 to about 30 ml of about 0.01 μg to about 10 μg of cytochalasin B per ml of liquid vehicle.
Claim 19
Dependent Claim 19 words
The kit of claim 1 wherein the vial is labeled for use in treating or inhibiting stenosis or restenosis.

References Cited (Backward Citations)

US3010965A Cited
US2914563A Cited
US3168565A Cited
GB1015787A Cited
US4536516A Cited
US3288806A Cited
US3445473A Cited
US3634517A Cited
USRE32944E Cited
US3940422A Cited
US4070484A Cited
FR2255063B1 Cited
US4093709A Cited
US5521171A Cited
US4133814A Cited
US4230862A Cited
US4323707A Cited
US4428963A Cited
GB1587084A Cited
US4317915A Cited
US4205685A Cited
US4235988A Cited
EP0002341B1 Cited
US4310523A Cited
US4221785A Cited
US5082834A Cited
US4440754A Cited
US4239778A Cited
US4732763A Cited
US4219656A Cited
US4315028A Cited
US4307111A Cited
US4382143A Cited
EP0024096B1 Cited
US4287190A Cited
US4487780A Cited
US5324736A Cited
US5098903A Cited
US4282246A Cited
US5658951A Cited
US5658927A Cited
US4332791A Cited
US4339429A Cited
US4442119A Cited
US4389330A Cited
US5332584A Cited
US4675189A Cited
EP0054168B1 Cited
US5047431A Cited
US4418068A Cited
US4380635A Cited
US4670428A Cited
US4485096A Cited
US5015666A Cited
US4879315A Cited
US5114847A Cited
US4485097A Cited
EP0095875B1 Cited
US4657928A Cited
US4952607A Cited
USRE33403E Cited
US4696949A Cited
US4996225A Cited
US5491173A Cited
US5656587A Cited
US5705477A Cited
US4512762A Cited
US4577636A Cited
US4491574A Cited
US4629694A Cited
US4555402A Cited
US4664097A Cited
US4705647A Cited
US4840939A Cited
US4757059A Cited
US4758554A Cited
US4758555A Cited
US4867973A Cited
US5226430A Cited
US4767758A Cited
US4897255A Cited
US4760051A Cited
US4605644A Cited
US5482851A Cited
US5284763A Cited
US4824436A Cited
US5262319A Cited
US4826672A Cited
US5470876A Cited
US4824661A Cited
US4853377A Cited
US4906452A Cited
US4744981A Cited
US5316766A Cited
US4935415A Cited
US4859585A Cited
US4962091A Cited
US4879225A Cited
US5314679A Cited
US5216021A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2005-12-09 2006-06-10 2006-12-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2009-12-09 2010-06-10 2010-12-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2013-12-09 2014-06-10 2014-12-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag